The short version of glucagon receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-21. Anything still debated is marked as such rather than presented as settled.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
| Property | Value | Notes |
|---|---|---|
| Trial design | Randomized, double-blind, placebo-controlled | Frequently includes dose-escalation arms |
| Weight endpoint | Percent change from baseline | Reported at a prespecified week |
| Liver fat endpoint | MRI proton density fat fraction | Non-invasive imaging measure |
| Body composition method | Dual-energy X-ray absorptiometry | Separates fat mass from lean mass |
| Common adverse events | Nausea, diarrhea, vomiting | Reported most often during dose escalation |
Identification and purity assessment rely on established analytical techniques. Reverse-phase high-performance liquid chromatography separates the compound from related impurities and degradation products. Mass spectrometry confirms molecular identity and detects modifications that change the expected mass. Additional methods such as amino acid analysis or capillary electrophoresis may be used for verification. Small differences in sample preparation can influence results, so procedures are usually controlled and documented in detail. Consistency between runs supports confidence in reported values.
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Solid material is generally held at -20 °C or colder, while reconstituted solutions are kept at 2-8 °C and used within a short window. Buffers that maintain a slightly acidic to neutral pH tend to improve short-term peptide stability. Repeated warming and cooling of stock solutions promotes aggregation and should be avoided. Container closures should remain intact, since adsorption to some plastics can reduce the amount of peptide in solution.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatographic profiles reveal related impurities, truncated sequences, and oxidation products, while mass measurement confirms the expected molecular mass. Purity values for research material are typically reported as a percentage by peak area. Reference standards help calibrate retention behavior across instruments. Independent laboratories emphasize method suitability because results depend heavily on column chemistry, gradient, and detection wavelength. Batch-to-batch comparison relies on the same validated method.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
== External links == Actin Staining Techniques (Live and Fixed Cell Staining) Eukaryotic Linear Motif resource motif class LIG_Actin_RPEL_3 Eukaryotic Linear Motif resource motif class LIG_Actin_WH2_1 Eukaryotic Linear Motif resource motif class LIG_Actin_WH2_2 3D macromolecular structures of actin filaments from the EM Data Bank(EMDB)
More recently, the initiative focused on improving security around Mexico's southern border and countering the production and trafficking of heroin and fentanyl. Until March 2017, more than $1.6bn has been invested in the Merida initiative, of which almost $900,000 was spent on protective equipment necessary for the secured demolishing of narcotic labs. In Mexico, the DEA combats operations of DTOs by conducting bilateral investigations with foreign counterparts, providing investigative assistance and leads to DEA domestic offices and other agencies, providing training and technical equipment to 'host nation participants to initiate and carry out complex criminal investigations, providing assistance in developing drug control laws and regulations, and providing training and material support to foreign law enforcement counterparts'.
== Limitations == Several factors complicate simple correlation of obsidian hydration band thickness with absolute age. Temperature is known to speed up the hydration process. Thus, artifacts exposed to higher temperatures, for example by being at lower elevation, seem to hydrate faster. As well, obsidian chemistry, including the intrinsic water content, seems to affect the rate of hydration. Once an archeologist can control for the geochemical signature of the obsidian (e.g., the "source") and temperature (usually approximated using an "effective hydration temperature" or EHT coefficient), he or she may be able to date the artifact using the obsidian hydration technique. Water vapor pressure may also affect the rate of obsidian hydration. The reliability of the method based on Friedman's empirical age equation (x²=kt, where x is the thickness of the hydration rim, k is the diffusion coefficient, and t is the time) is questioned from several grounds regarding temperature dependence, square root of time and determination of diffusion rate per sample and per site, as part of some successful attempts on the procedure and applications. The SIMS-SS age calculation procedure is separated into two major steps. The first step concerns the calculation of a 3rd order fitting polynomial of the SIMS profile (eq. 1). The second stage regards the determination of the saturation layer, i.e. its depth and concentration.
Sources: en.wikipedia.org
Also, the cost of purchasing and disposing of stationary phase media is eliminated. Another advantage of countercurrent chromatography is that experiments conducted in the laboratory can be scaled to industrial volumes. When gas chromatography or HPLC is carried out with large volumes, resolution is lost due to issues with surface-to-volume ratios and flow dynamics; this is avoided when both phases are liquid.
He was initiated into the Tau chapter of Alpha Chi Sigma at Cornell in 1949. At Cornell he elaborated and refined his Baker Lectures into his magnum opus, Principles of Polymer Chemistry which was published in 1953 by Cornell University Press. This quickly became a standard text for all workers in the field of polymers, and is still widely used to this day. Flory introduced the concept of excluded volume, coined by Werner Kuhn in 1934, to polymers. Excluded volume refers to the idea that one part of a long chain molecule can not occupy space that is already occupied by another part of the same molecule. Excluded volume causes the ends of a polymer chain in a solution to be further apart (on average) than they would be were there no excluded volume. The recognition that excluded volume was an important factor in analyzing long-chain molecules in solutions provided an important conceptual breakthrough, and led to the explanation of several puzzling experimental results of the day. It also led to the concept of the theta point, the set of conditions at which an experiment can be conducted that causes the excluded volume effect to be neutralized. At the theta point, the chain reverts to ideal chain characteristics – the long-range interactions arising from excluded volume are eliminated, allowing the experimenter to more easily measure short-range features such as structural geometry, bond rotation potentials, and steric interactions between near-neighboring groups.
Candesartan is an angiotensin receptor blocker (ARB) primarily used to treat high blood pressure and congestive heart failure. It is always administered in its inactive prodrug form, candesartan cilexetil, which is converted to the active drug during absorption in the gastrointestinal tract. Like olmesartan, candesartan is a cascading prodrug, a feature that influences its pharmacokinetics. It has good bioavailability and is considered one of the most potent AT1 receptor antagonists by weight. Its effective maintenance dose is also relatively low. It was patented in 1990 and approved for medical use in 1997.
The primary structure of a protein refers to the sequence of amino acids in the polypeptide chain. The primary structure is held together by peptide bonds that are made during the process of protein biosynthesis. The two ends of the polypeptide chain are referred to as the carboxyl terminus (C-terminus) and the amino terminus (N-terminus) based on the nature of the free group on each extremity. Counting of residues always starts at the N-terminal end (NH2-group), which is the end where the amino group is not involved in a peptide bond. The primary structure of a protein is determined by the gene corresponding to the protein. A specific sequence of nucleotides in DNA is transcribed into mRNA, which is read by the ribosome in a process called translation. The sequence of amino acids in insulin was discovered by Frederick Sanger, establishing that proteins have defining amino acid sequences. The sequence of a protein is unique to that protein, and defines the structure and function of the protein. The sequence of a protein can be determined by methods such as Edman degradation or tandem mass spectrometry. Often, however, it is read directly from the sequence of the gene using the genetic code. It is strictly recommended to use the words "amino acid residues" when discussing proteins because when a peptide bond is formed, a water molecule is lost, and therefore proteins are made up of amino acid residues. Post-translational modifications such as phosphorylations and glycosylations are usually also considered a part of the primary structure, and cannot be read from the gene.
Sources: en.wikipedia.org
The MEROPS online database for peptidases and their inhibitors: I04.953 Archived 2019-10-16 at the Wayback Machine Angiotensins at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Human AGT genome location and AGT gene details page in the UCSC Genome Browser. Overview of all the structural information available in the PDB for UniProt: P01019 (Angiotensin) at the PDBe-KB.
. A 2022 paper provides a less costly, dynamical and recurrent solution of the Navier-Stokes equation for 3D turbulent fluid flows. On suitably short time scales, the dynamics of turbulence is deterministic.
=== India === The Communist Party of India and its affiliates condemned the US strikes in Venezuela. The Indian National Congress denounced the US's unilateral actions in Venezuela, accusing the United States for transgressing the settled principles of international law, the United Nations Charter and numerous international treaties.
=== United Kingdom === In the UK, the Pharmaceutical Price Regulation Scheme is intended to ensure that the National Health Service is able to purchase drugs at reasonable prices. The prices are negotiated between the Department of Health, acting with the authority of Northern Ireland and the UK Government, and the representatives of the Pharmaceutical industry brands, the Association of the British Pharmaceutical Industry (ABPI). For 2017 this payment percentage set by the PPRS will be 4,75%.
== X-axis: m/z (mass-to-charge ratio) == The x-axis of a mass spectrum represents a relationship between the mass of a given ion and the number of elementary charges that it carries. This is written as the IUPAC standard m/z to denote the quantity formed by dividing the mass of an ion (in daltons) by the dalton unit and by its charge number (positive absolute value). Thus, m/z is a dimensionless quantity with no associated units. Despite carrying neither units of mass nor charge, the m/z is referred to as the mass-to-charge ratio of an ion. However, this is distinct from the mass-to-charge ratio, m/Q (SI standard units kg/C), which is commonly used in physics. The m/z is used in applied mass spectrometry because convenient and intuitive numerical relationships naturally arise when interpreting spectra. A single m/z value alone does not contain sufficient information to determine the mass or charge of an ion. However, mass information may be extracted when considering the whole spectrum, such as the spacing of isotopes or the observation of multiple charge states of the same molecule. These relationships and the relationship to the mass of the ion in daltons tend toward approximately rational number values in m/z space. For example, ions with one charge exhibit spacing between isotopes of 1 and the mass of the ion in daltons is numerically equal to the m/z. The IUPAC Gold Book gives an example of appropriate use: "for the ion C7H72+, m/z equals 45.5".
Sources: en.wikipedia.org
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.
Mechanistic measures such as energy expenditure and liver fat change come from small substudies and should be read as preliminary. Long-term clinical outcomes are not yet available. Average weight loss figures are better supported than explanations for how the loss is achieved.
Endpoints reported at different weeks, in different baseline BMI ranges, or under different dose-escalation schedules are not directly comparable. Studies in type 2 diabetes often show smaller weight changes than studies in obesity without diabetes. Reporting the population alongside the number keeps comparisons honest.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.